RAYMEI

Raymei is a clinical-stage biotechnology company focused on developing next-generation gene therapies for ophthalmic and neurological diseases. Based in Suzhou, China, the company utilizes a proprietary adeno-associated virus (AAV) platform to create long-lasting treatments for chronic conditions with high unmet medical needs. Its lead program, RM-001, is an AAV-based gene therapy currently in clinical trials for neovascular age-related macular degeneration (nAMD). Raymei's approach aims to transform the treatment landscape by providing a "one-and-done" solution that reduces the burden of frequent intravitreal injections for patients. The company is supported by a strong syndicate of global life science investors, including Qiming Venture Partners and Lilly Asia Ventures.